Wednesday, November 12, 2025
Continuity at the Top: Dr. Hans-Peter Hubmann remains Chairman of the German Institute for Drug Testing (DAPI)
The members of the German Institute for Drug Testing (DAPI) have elected a new board, opting for continuity and experience: Dr. Hans-Peter Hubmann (61) was unanimously re-elected as Chairman. He has led the institute since 2021 and will continue to do so for another four-year term.
“We contribute through our publications and expert reports to the improvement of drug therapy safety. In addition, our analyses support pharmacists’ chambers and associations in preparing negotiations, training sessions, and events. I am very pleased to continue leading DAPI in the coming years,” said Hubmann after his re-election.
Cathrin Burs (62), President of the Chamber of Pharmacists of Lower Saxony, remains Deputy Chairwoman, also elected unanimously.
The newly elected board members are:
- Thomas Benkert (69), Honorary President of the Federal Chamber of Pharmacists
- Dr. Peter Froese (65), Chairman of the Supervisory Board of GEDISA mbH
- Prof. Dr. Martin Schulz (66), Managing Director for Pharmaceuticals at ABDA and Chairman of the Drug Commission of German Pharmacists (AMK)
Prof. Dr. Schulz joins the board as a new member, having previously served as one of DAPI’s two Managing Directors. Dr. Sebastian Schmitz (66), Chief Executive Officer of ABDA, did not stand for re-election and has left the board.
The DAPI is a non-profit association supported by 15 regional chambers of pharmacists and 15 regional pharmacists’ associations. Around 250 individual members also contribute to its work through their annual membership fees. DAPI provides valuable data analyses and expert reports that make a significant contribution to the advancement of pharmaceutical care and public health in Germany.
Related articles
Annika Hollmann to Head Communications at DSO
As of November 1, Annika Hollmann has taken over as Head of Communications at the German Organ Transplantation Foundation (DSO), succeeding Birgit Blome, who is retiring.
Gregor Müller becomes new Managing Director at Thieme RECOM
As of November 1, 2025, Gregor Müller has taken on the role of Managing Director at Thieme RECOM. The experienced health economist aims to advance digital transformation and expand the company’s product portfolio.
Thomas Meier becomes new CEO of Medios AG
The Supervisory Board of Medios AG has appointed Thomas Meier as CEO effective February 1, 2026. He succeeds Matthias Gaertner, who will remain in office until the end of 2025.
Dr. Johanna Graf becomes Deputy Chair of BEYOND FLUORID
Renowned dentist and author Dr. Johanna Graf becomes Deputy Chair of the Scientific Advisory Board at BEYOND FLUORID, reinforcing the initiative’s scientific independence.
Dr. Romy Ermler becomes new President of the German Dental Association
The Federal Assembly of the German Dental Association has elected Dr. Romy Ermler as its new President. Together with Dr. Ralf Hausweiler and Dr. Doris Seiz, she will lead the new Executive Board.
Philipp Brunner becomes CFO of Plan.Net Group
Effective November 1, Philipp Brunner joins Plan.Net Group as the new CFO, succeeding Dr. Ingo Stein. He will oversee all financial operations and strengthen the group’s digital finance strategy.
Two new leaders join Chiesi’s management team
Chiesi’s leadership team is growing: With Christine Contré and Sven Noffke, Chiesi gains two experienced professionals in Medical Affairs and Legal & Compliance.
Tomas Mihal appointed new Head of STADA Germany
STADA has appointed Tomas Mihal as its new Head of Germany and member of the global STADA Executive Committee. The experienced manager will further strengthen the company’s position and drive sustainable growth across all three business segments.